Lexicon Pharmaceuticals (LXRX) Change in Accured Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Change in Accured Expenses for 17 consecutive years, with -$6.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 68.2% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$15.4 million (down 795.94% YoY), while the FY2025 annual figure was -$30.2 million, down 304.19% from the prior year.
• Change in Accured Expenses slipped to -$6.9 million in Q1 2026 per LXRX's latest filing, from -$5.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $11.1 million in Q2 2025 and bottomed at -$21.7 million in Q1 2025.
• Historically, Change in Accured Expenses has averaged -$928823.5 across 5 years, with a median of -$2.1 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 750.07% — and 2025, when it tumbled 257.86%.
• Lexicon Pharmaceuticals' Change in Accured Expenses stood at $4.7 million in 2022, then sank by 156.31% to -$2.7 million in 2023, then surged by 443.93% to $9.1 million in 2024, then sank by 161.89% to -$5.6 million in 2025, then retreated by 22.13% to -$6.9 million in 2026.
• Business Quant data shows LXRX's Change in Accured Expenses at -$6.9 million in Q1 2026, -$5.6 million in Q4 2025, and -$14.0 million in Q3 2025.